p38 kinase inhibitor approved for idiopathic pulmonary fibrosis von Moran, Nuala

Volltext

Public sector seeks to bridge 'valley of death' von Moran, Nuala

Volltext

FDA approves Galafold, a triumph for Amicus von Moran, Nuala

Volltext

Biotech startups woo increasing numbers of crowdfunders von Moran, Nuala

Volltext

Shire's replacement enzymes validate gene activation von Moran, Nuala

Volltext

First gene therapy nears landmark European market authorization von Moran, Nuala

Volltext

Patenting natural products just got harder von Harrison, Charlotte

Volltext

Incyte comes of age with JAK inhibitor approval von Moran, Nuala

Volltext

Mouse platforms jostle for slice of humanized antibody market von Moran, Nuala

Volltext

Shire shifts towards rare diseases von Moran, Nuala

Volltext

Shire shifts towards rare diseases von Moran, Nuala

Volltext

AstraZeneca juggernaut heads for Cambridge von Moran, Nuala

Volltext

10,000 rare-disease genomes sequenced von Moran, Nuala

Volltext

J&J in trio of European deals von Moran, Nuala

Volltext

Argos attracts unorthodox backers von Moran, Nuala

Volltext

From the bottom of a DNA cocktail glass von Moran, Nuala

Volltext

Brüstle patent holds up in Germany von Moran, Nuala

Volltext

Biotechs to tap into Horizon 2020's $93 billion von Moran, Nuala

Volltext

Forma skips tech transfer brokers von Moran, Nuala

Volltext

European court bans embryonic stem cell patents von Moran, Nuala

Volltext